Terms ending in 2036
Every in-force patent on Alector LLC's record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,084,875 | ANTI-TREM2 Antibodies and Methods of Use Thereof In force · High confidence | Alector LLC | In force | High confidence | |
| US 12,110,327 | Anti-TREM1 Antibodies and Methods of Use Thereof In force · High confidence | Alector LLC | In force | High confidence | |
| US 10,087,255 | Anti-Sortilin Antibodies and Methods of Use Thereof In force · High confidence | Alector LLC | In force | High confidence | |
| US 10,308,718 | Anti-Sortilin Antibodies and Methods of Use Thereof In force · High confidence | Alector LLC | In force | High confidence | |
| US 10,428,150 | Anti-Sortilin Antibodies and Methods of Use Thereof In force · High confidence | Alector LLC | In force | High confidence | |
| US 11,208,488 | Methods of Increasing Progranulin Levels Using Anti-Sortilin Antibodies In force · High confidence | Alector LLC | In force | High confidence | |
| US 11,339,223 | Methods of Use of Anti-Sortilin Antibodies for Treating a Disease, Disorder, or Injury In force · High confidence | Alector LLC | In force | High confidence | |
| US 11,186,645 | Isolated Nucleic Acids Encoding Anti-Sortilin Antibodies In force · High confidence | Alector LLC | In force | High confidence | |
| US 11,174,313 | ANTI-CD33 Antibodies and Methods of Use Thereof In force · High confidence | Alector LLC | In force | High confidence | |
| US 11,136,390 | ANTI-CD33 Antibodies and Methods of Use Thereof In force · High confidence | Alector LLC | In force | High confidence | |
| 4 more term ends in 2036 · Pro | |||||
10 of 14 patents shown. Soonest term end first, then patent number.
Pro members see all 14.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.